Document:

Exhibit 10.8

 

	AMENDMENT
    OF SOLICITATION OF CONTRACT	1.
    CONTRACT ID CODE	PAGE
    OF PAGES	 
	1	4	 
	2. AMENDMENT/MODICATION NO.

    P00001
	3. EFFECTIVE DATE

    See Block 16c
	4.
    REQUISITION/PURCHASE REQ. NO.	5. PROJECT
    NO. (if applicable)	 
	6. ISSUED
    BYCODE	NCI-EXEC	7.
    ADMINISTERED BY (if other than Item 6)CODE	NCI	 
	National Institutes of Health

    National Cancer Institute

    Bethesda, MD 20892-7511
	 	National Institutes of Health

    National Cancer Institute

    Bethesda, MD 20892-7511
	 
	8. NAME AND ADDRESS OF CONTRACTOR
    (No., street, county, State and Zip Code)

     

    AETHLON MEDICAL, INC.:1296382

    9635 GRANITE RIDGE DRIVE SUITE 100

    SAN DIEGO CA 921232678
	(x)	9A.
    AMENDMENT OF SOLICITAITON NO.	 
	9B.
    DATED (SEE ITEM 11)	 
	x
	10A. MODIFICATION OF CONTRACT/ORDER
    NO.

    75N91019C00042
	 
	10B. DATED (SEE ITEM 13)

    09/12/2019
	 
	CODE	FACILITY
    CODE	 
	 	 
	11.
    THIS ITEM ONLY APPLIES TO AMENDMENTS OF SOLICITIONS	 
	☐	The above
    numbered solicitation is amended as set forth in Item 14. The hour and date specified for receipt of Offers            ☐ is
    extended.                         ☐ is
    not extended. Offers must acknowledge receipt of this amendment prior to the hour and date specified in the solicitation or as amended,
    by one of the following methods: (a) By completing Items Band 15, and returning _____________ copies of the amendment; (b) By acknowledging
    receipt of this amendment on each copy of the offer submitted; or (c) By separate letter or telegram which includes a reference to
    the solicitation and amendment numbers. FAILURE OF YOUR ACKNOWLEDGEMENT TO BE RECEIVED AT THE PLACE DESIGNATED FOR THE RECEIPT OF
    OFFERS PRIOR TO THE HOUR AND DATE SPECIFIED MAY RESULT IN REJECTION OF YOUR OFFER. If by virtue of this amendment you desire to change
    an offer already submitted , such change may be made by telegram or letter, provided each telegram or letter makes reference to the
    solicitation and this amendment. and is received prior to the opening hour and date specified.	 
	12. ACCOUNTING AND APPOPRIATION
    DATE (if required)

    See Schedule
	 
	13.
    THIS ITEM ONLY APPLIES TO MODIRCATION OF CONTRACTS/ORDERS. IT MODIRES THE CONTRACT/ORDER NO. AS DESCRIBED IN ITEM 14.	 
	CHECK
    ONE	A. THIS CHANGE ORDER IS ISSUED PURSUANT TO: (Specify authority) THE CHANGES SET FORTH IN ITEM 14 ARE MADE IN THE CONTRACT ORDER NO. IN ITEM 10A.

                                                                                 
	 
	 

                                                                                 
	 
	 

                                                                                 
	B. THE ABOVE NUMBERED CONTRACT/ORDER IS MODIFIED TO REFLECT THE ADMINISTRATIVE CHANGES (such as changes in paying office, appropriation date, etc.) SET FORTH IN ITEM 14, PURSUANT TO THE AUTHORITY OF FAR 43.103(b).

                                                                                 
	 
	X	C. THIS SUPPLEMENTAL AGREEMENT
    IS ENTERED INTO PURSUANT TO AUTHORITY OF:

     

    FAR 1.602-1, Authority; FAR 43.102(a)
    (3) Mutual Agreement of the

     
	 
	 	(Specify tyle of modification and authority)

                                                                                 
	 
	E. IMPORTANT:	Contractor	☐  is
    not.	☒ is required to sign
    this document and return          1         
    copies to the issuing office.	 
	 	 	 	 	 
	14. DESCRIPTION OF AMENDMENT/MODIFICATION (Organized
    by UCF section headings, including solicitation/contract subject matter where feasible.)	 
	 	 
	The purpose of this modification
    is to 1) revise the period of performance, 2) revise the milestone schedules contained in the Statement of Work, and 3) update Articles
    B.2., F.1., C.1., and Section J, to reflect these changes. No changes are being made to the contract price and no funds are being
    obligated by this modification.

                                                             

    PREVIOUS
    PERIOD OF PERFORMANCE:    September 16, 2019 - September 15, 2021 (UNCHANGED)

    NEW
    PERIOD OF PERFORMANCE:              September 16, 2019 - September 15, 2022 (CHANGED)

    FUNDS
    CURRENTLY OBLIGATED:              $1,860,561 (UNCHANGED)

     

    ALL OTHER CONTRACT TERMS AND CONDITIONS
    REMAIN UNCHANGED.

     

    Continued...

     

    Except as provided herein, all
    terms and conditions of the document referenced in Item 9 A or 10A. as heretofore changed, remains unchanged and in full force and
    effect.
	 
	15A. NAME AND TITLE OF SIGNER
    (Type or print)

    

    James B. Frakes, Chief Financial Officer	16A. NAME AND TITLE OF CONTRACTING
    OFFICER (Type or print)

    

    CHRISTOPHER E. MILLS	 
	15B. CONTRACTOR/OFFEROR	15C. DATE SIGNED	16B. UNITED STATES OF AMERICA	16C. DATE SIGNED	 
	_/s/
    James B. Frakes, Chief Financial Officer

    (Signature of person authorize to sign)	10/16/20	_/s/
    Christopher E. Mills-S____________________

    (Signature of Contracting Officer)	 	 
	 	 	 	 	 
	NSN 7540-01-152-8070

    Previous edition unusable	STANDARD FORM 30 (REV. 10-83)

    Prescribed by GSA

    FAR (48 CFR) 53.243	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 

 

    	 	1	 

     

    

 

	CONTINUATION SHEET	
    REFERENCE NO. OF DOCUMENT BEING CONTINUED

    75N91019C00042/P00001
	PAGE OF
	2	4
	
    NAME OF OFFEROR OR CONTRACTOR

    AETHLON MEDICAL, INC.: 1296382

	ITEM NO.

(A)	SUPPLIES/SERVICES

(B)	QUANTITY

(C)	UNIT

(D)	UNIT PRICE

(E)	AMOUNT

(F)
	 	
    Delivery: 09/15/2022

    Delivery Location Code: MEDICAL CENTER DR

    9609 Medical Center Drive, Rockvill

    9609 Medical Center Drive Rockville MD 20850 US

     
	 	 	 	 
	 	
    Payment:

    Approved By, NCI Branch A Invoices

    Paid By: NIH Commercial Accounts Br

    2115 East Jefferson St, MSC 8500

    Room 4B-432

    Bethesda, MD 20892-8500

    Change Item 1 to read as follows(amount shown is the
    obligated amount):

     
	 	 	 	 
	1.	
    Topic 359: A Device Prototype for
    Isolation of Melanoma Exosomes for Diagnostics and Treatment Monitoring

    Obligated Amount: $0.00

    Product/Service Code: AN13

    Product/Service Description: R&D- MEDICAL:

    BIOMEDICAL (ADVANCED DEVELOPMENT)

     
	 	 	 	0.00
	 	
    Project Data:

    125132.1.HNC1 NCI OD OFFICE OF THE DIRECTOR.2555

    RESEARCH AND DEVELOPMENT.09/03/2019

    Accounting Info:

    08024920191DA0.2019.03.C100.HNC1000000C.E.00014.40

    6.SBIR.2550A.61000001.9999.9999.9999

    Funded: $0.00

     
	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 	 

	NSN 7540-01-152-8067	OPTIONAL FORM 336 (4-86)

Sponsored by GSA

FAR (48 CFR) 53.110

 

 

    	 	2	 

     

    

 

Beginning with the effective date of this modification, the contractor
and the government mutually agree as follows: (bold, italicized text denotes modified contract language):

 

ARTICLE B.2. PRICES, revised paragraph 2.

 

		1.	The total fixed price of this contract is $1,860,561.

		2.	Upon delivery and acceptance of the services described in SECTION C of this contract and identified in the schedule of charges below,
the Government shall pay to the Contractor the unit price(s) set forth below:

 

PAYMENT SCHEDULE, Revised

 

	Description	Amount ($)
	Kick-Off Presentation	$ 206,729
	Quarterly Report 1	$ 206,729
	Quarterly Report 2	$ 206,729
	Quarterly Report 3	$ 206,729
	
    Quarterly Report 4, SBIR Program Life Cycle Certification,

    Annual Updated Commercialization Plan
	$ 206,729 114,849.44
	Quarterly Report 5	$ 206,729 114,849.44
	Quarterly Report 6	$ 206,729 114,849.44
	Quarterly Report 7	$ 206,729 114,849.44
	Quarterly Report 8	114,849.44
	Quarterly Report 9	114,849.44
	Quarterly Report 10	114,849.44
	Quarterly Report 11	114,849.44
	
    Final Report, Contract Outcomes Report, Final presentation,

    and all other contract deliverables
	$ 206,729 114,849.44
	TOTAL FIXED PRICE	$ 1,860,561

 

ARTICLE F.1. PERIOD OF PERFORMANCE

The period of performance of this contract shall
be from September 16, 2019 through September 15, 2021 2022

.

ARTICLE C.1. STATEMENT OF WORK

a. Independently and not as an agent of the Government,
the Contractor shall furnish all the necessary services, qualified personnel, material, equipment, and facilities, not otherwise provided
by the Government as needed to perform the Statement of Work, dated August 28, 2019 July 1, 2020, set forth
in SECTION J-List of Attachments, attached hereto and made a part of this contract.

 

SECTION J - LIST OF ATTACHMENTS

The following documents are attached and incorporated in this contract:

 

1. Statement of Work

Statement of Work, dated August
28, 2019 July 1, 2020, 3 pages.

 

End of Modification P00001

 

All other terms and conditions of this contract remain unchanged
and in full force and effect.

 

 

 

 

    	 	3Exhibit 10.1

 

MEIHUA
INTERNATIONAL MEDICAL TECHNOLOGIES CO., LTD.

 

DIRECTOR SERVICE AGREEMENT

 

This Director Service Agreement
(the “Agreement”) is made and entered into as of June 28, 2022, by and between Meihua International Medical
Technologies Co., Ltd., a Cayman Islands corporation (the “Company”), and Wenzhang Jia, an individual (the
“Director”).

 

I. SERVICES

 

A. Service on the
Board of Directors. The Director has been appointed as an Independent Director of the Company’s Board of Directors (the “Board”),
with his service having commenced upon June 10, 2022 (the “Effective Date”) and to continue until the earlier of the
date on which Director ceases to be a member of the Board for any reason or the date of termination of this Agreement in accordance with
this Section V(B) hereof (such earlier date being the “Expiration Date”). The Board shall consist of the Director
and such other members as nominated and elected from time to time pursuant to the then current Memorandum and Articles of Association
of the Company (the “Articles”).

 

B. Director Services.
Director’s services to the Company hereunder shall include service as a member of the Board to direct the business of the Company
in accordance with applicable law and the then current Articles. Director shall devote such time and attention to the business and affairs
of the Company as is necessary to perform his duties as a Director in a faithful and competent manner. Director shall comply with all
laws, rules, and regulations applicable to the Company and its business. Director shall further comply with all policies and codes of
conduct which the Company shall reasonably determine are necessary for the proper functioning of its business (collectively, the “Director
Services”).

 

II. COMPENSATION

 

A. Expense Reimbursement.
The Company shall reimburse Director for all reasonable travel and other out-of-pocket expenses incurred in connection with the Director
Services rendered by Director.

 

B. Cash Fees to Director.
The Company agrees to pay Director a fee of $2,500 per month for each month of service as a Director, paid on the last day of each calendar
month. In the event Director ceases to be a member of the Board on a day other than the last day of a calendar month, the Director shall
be paid the pro rata portion of the monthly fee for his final month of service.

 

C. Stock Options.
Immediately upon the Effective Date, the Company will grant to the Director options to purchase $10,000 of the Company’s Ordinary
Shares, par value $0.0005 per share, at an exercise price equal to the per share closing price on The Nasdaq Capital Market on the date
of issuance. The options shall be exercisable at any for a period of 10 years from the Effective Date. The options shall vest and become
exercisable by the Director in equal monthly installments over the course of the Director’s initial year of service, that is over
a 12 month period. In the event that the Director ceases to be a member of the Board prior to the end of one year of service, all unvested
stock options awarded hereunder shall be forfeited. The director may exercise such options on a cashless basis.

 

D. Director and Officer
Liability Insurance. The Company’s proposed director and officer liability insurance policy shall provide Director with coverage
for damages and losses incurred in connection with the Director Services.

  

    1

     

    

 

III. DUTIES OF DIRECTOR

 

A. Fiduciary Duties.
In fulfilling his responsibilities, Director shall be charged with a fiduciary duty to the Company and all of its shareholders. Director
shall be attentive to and inform himself of all material facts regarding a decision before taking action. In addition, Director’s
actions shall be motivated solely by the best interests of the Company and its shareholders.

 

B. Confidentiality.
During the term of this Agreement, and for a period of one (1) year after the Expiration Date, Director shall maintain in strict
confidence all information he has obtained or shall obtain from the Company which the Company has designated as “confidential”
or which is, by its nature confidential, relating to the Company’s business, operations, properties, assets, services, condition
(financial or otherwise), liabilities, employee relations, customers, suppliers, prospects, technology, or trade secrets, except to the
extent such information (i) is in the public domain through no act or omission of the Company, or (ii) is required to be disclosed
by law or a valid order by a court or other governmental body (the “Confidential Information”).

 

C. Nondisclosure
and Nonuse Obligations. Director will use the Confidential Information solely to perform the Director Services for the benefit of
the Company. Director will treat all Confidential Information of the Company with the same degree of care as Director treats his own Confidential
Information, and Director will use his best efforts to protect the Confidential Information. Director will not use the Confidential Information
for his own benefit or the benefit of any other person or entity, except as may be specifically permitted in this Agreement. Director
will immediately give notice to the Company of any unauthorized use or disclosure by or through him, or of which he becomes aware, of
the Confidential Information. Director agrees to assist the Company in remedying any such unauthorized use or disclosure of the Confidential
Information.

 

D. Return of
the Company Property. All materials furnished to Director by the Company, whether delivered to Director by the Company or made by
Director in the performance of Director Services under this Agreement (the “Company Property”) are the sole and exclusive
property of the Company. Director agrees to promptly deliver the original and any copies of the Company Property to the Company at any
time upon the Company’s request. Upon termination of this Agreement by either party for any reason, Director agrees to promptly
deliver to the Company or destroy, at the Company’s option, the original and any copies of the Company Property. Director agrees
to certify in writing that Director has so returned or destroyed all such the Company Property.

 

IV. COVENANTS OF DIRECTOR

 

A. No Conflict of
Interest. For so long as Director is a member of the Board, Director shall not be employed by, own, manage, control or participate
in the ownership, management, operation or control of any business entity that is competitive with the Company or otherwise undertake
any obligation inconsistent with the terms hereof, provided that Director may continue Director’s current affiliations or other
current relationships in existence on the date of this Agreement (collectively, the “Current Affiliations”). For a
period of one (1) year after the Expiration Date, Director shall not be employed by, operate, or manage any business entity that
is competitive with the Company. This Agreement is subject to the current terms and agreements governing Director’s relationship
with the Current Affiliations, and nothing in this Agreement is intended to be or will be construed to inhibit or limit any of Director’s
obligations to the Current Affiliations. Director represents that nothing in this Agreement conflicts with Director’s obligations
to the Current Affiliations. A business entity shall be deemed to be “competitive with the Company” for purpose of this Article
IV only if and to the extent it engages in a business substantially similar to the Company’s natural products and ingredients businesses.

 

B. Noninterference
with Business. During the term of this Agreement, and for a period of one (1) year after the Expiration Date, Director agrees
not to interfere with the business of the Company in any manner. By way of example and not of limitation, Director agrees not to solicit
or induce any employee, independent contractor, customer, or supplier of the Company to terminate or breach his or her employment, contractual
or other relationship with the Company.

 

C. Mutual Non-Disparagement.
Director and the Company mutually agree to forbear from making, causing to be made, publishing, ratifying, or endorsing any and all disparaging
remarks, derogatory statements or comments made to any party with respect to either of them. Further, the parties hereto agree to forbear
from making any public or non-confidential statement with respect to any claim or complain against either party without the mutual consent
of each of them, to be given in advance of any such statement.

 

    2

     

    

 

V. TERM AND TERMINATION

 

A. Term. This
Agreement is effective on the Effective Date and will continue for one year. In the absence of any agreement in writing to the contrary,
this Agreement shall continue to renew for successive one (1) year terms on each anniversary of the Effective Date. Upon each annual renewal,
and in the absence of a written agreement to the contrary:

 

	 	1.	The Director shall receive an additional grant of stock options (a “Renewal Grant”). The dollar value, vesting, and other terms of the options included in each Renewal Grant shall be under as set forth in Section II(C), above, (and, if applicable, Section II(D), above, for Committee Grants) except that the number of options granted shall be determined with reference to the volume weighted average price for the Company’s Ordinary Shares during the thirty (30) trading days preceding the annual renewal date; and

 

	 	2.	The Director shall continue to receive the monthly stipend as set forth in Section II(B), above, and shall continue to be reimbursed for expenses as set forth in Section II(A), above.

 

B. Termination.
This Agreement, and the Director’s service as a member of the Board, shall terminate:

 

	 	1.	at any time upon thirty (30) days prior written notice by the Director of his resignation;

 

	 	2.	upon the close of any shareholder’s meeting for the election of directors, if the Director is not re-elected to the Board by the Company’s shareholders at such meeting;

 

	 	3.	upon removal of the Director by Ordinary Resolution as provided in the Articles;

 

	 	4.	automatically if, at any time, the Director becomes disqualified under the terms of the Articles; or

 

	 	5.	upon a determination by a majority of the Board (not including the Director), that:

 

	 	●	the Director has committed a breach a of any of Director’s obligations under this Agreement;

 

		●	the Director is or has become prohibited by any law, regulation,
or rule applicable to the Company from serving as a member of the Board;

 

		●	the Director has become unable to perform his duties under
this Agreement due to health reasons, disability, or being of unsound mind, unless the Company can accommodate the Director’s health
impairment or disability without the Company incurring undue hardship;

 

		●	the Director is guilty of any serious misconduct or serious
neglect in the discharge of the Director’s duties hereunder;

 

		●	the Director’s actions or omissions bring the name
or reputation of the Company, or any of Company’s affiliates, subsidiaries, or parent (each a “Group Member”) into
serious disrepute or prejudices the business interests of the Company or any Group Member; or

 

		●	the Director is charged or convicted of any criminal offence
other than an offence which, in the reasonable opinion of the Board, does not affect the Director’s position as a director (bearing
in mind the nature of the duties in which the Director is engaged and the capacities in which the Director is engaged).

 

C. Survival. The
rights and obligations contained in Articles III and IV will survive any termination or expiration of this Agreement.

 

    3

     

    

 

VI. MISCELLANEOUS

 

A. Assignment.
Except as expressly permitted by this Agreement, neither party shall assign, delegate, or otherwise transfer any of its rights or obligations
under this Agreement without the prior written consent of the other party. Subject to the foregoing, this Agreement will be binding upon
and inure to the benefit of the parties hereto and their respective heirs, legal representatives, successors, and assigns.

 

B. No Waiver.
The failure of any party to insist upon the strict observance and performance of the terms of this Agreement shall not be deemed a waiver
of other obligations hereunder, nor shall it be considered a future or continuing waiver of the same terms.

  

C. Notices.
Any notice required or permitted by this Agreement shall be in writing and shall be delivered as follows with notice deemed given as indicated:
(i) by personal delivery when delivered personally; (ii) by overnight courier upon written verification of receipt; (iii) by
facsimile transmission upon acknowledgment of receipt of electronic transmission; or (iv) by certified or registered mail, return
receipt requested, upon verification of receipt. Notice shall be sent to the addresses set forth below or such other address as either
party may specify in writing.

 

To the Company:

 

Mr. Yulin Wang, CEO

88 Tongda Road, Touqiao Town

Guangling District, Yangzhou, 225000

People’s Republic of China

 

To Director:

 

Mr. Wenzhang Jia

[Director’s Address]

 

Governing Law. This
Agreement shall be governed in all respects by the laws of the Cayman Islands, without regard to conflicts of law principles thereof.

 

D. Severability.
Should any provisions of this Agreement be held by a court of law to be illegal, invalid, or unenforceable, the legality, validity, and
enforceability of the remaining provisions of this Agreement shall not be affected or impaired thereby.

 

E. Entire Agreement.
This Agreement constitutes the entire agreement between the parties relating to this subject matter and supersedes all prior or contemporaneous
oral or written agreements concerning such subject matter. The terms of this Agreement will govern all Director Services undertaken by
Director for the Company

 

F. Amendments.
This Agreement may only be amended, modified, or changed by an agreement signed by the Company and Director. The terms contained herein
may not be altered, supplemented, or interpreted by any course of dealing or practices.

 

G. Counterparts.
This Agreement may be executed in two counterparts, each of which shall be deemed an original, but all of which together shall constitute
one and the same instrument.

 

    4

     

    

  

IN WITNESS WHEREOF, the parties have executed this Agreement as of
the date first written above.

 

	
    By:  
	/s/ Yulin Wang

	 
	 	Yulin Wang

    
	 
	 	Chief Executive Officer	 

 

	Independent Director:	 
	
     

    
	 
	/s/ Wenzhang Jia	 
	Wenzhang Jia	 

 

 

5

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00346-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00346-of-00352.parquet"}]]